News...

CorDynamics to Exhibit Proven Cardiovascular Safety and Discovery Solutions at Society of Toxicology Meeting in Salt Lake City

Chicago, Illinois, December 2009 — CorDynamics heads to the Society of Toxicology 49th Annual Meeting, March 7-11, 2010 at the Salt Palace Convention Center in Salt Lake City, Utah. Dr. Michael Gralinski, CorDynamics CEO, will be among the experts available to meet with colleagues, clients and new customers.

“For CorDynamics, this meeting is an ideal place to highlight the proven solutions we provide for cardiovascular safety and discovery questions,” says Gralinski. “Our team has built our brand and client base on delivering decision-enabling isolated heart and screening telemetry results in a matter of days. These inherently affordable models maximize a return on outsourcing spending.”

CorDynamics also offers full-service GLP assessments needed for lead interrogation and regulatory submissions.

“Coupling our laboratories with our growing CorSolutions consulting operation, we truly are a ‘one-stop shop’,” says Gralinski.

CorDynamics, Inc. is a comprehensive contract research organization and consulting group focused on examining the cardiovascular effects of emerging drug candidates. The company provides support with discovery and preclinical safety pharmacology studies along with lead optimization screening and consulting for more than 100 biopharmaceutical clients.

To learn more about the company, please visit our website at www.cordynamics.com. To schedule a private consultation with Dr. Gralinski please contact us at mrg@cordynamics.com.

Contact:
Michael R. Gralinski, Ph.D., CEO
mrg@cordynamics.com
www.cordynamics.com